To isolate NSCLC sublines that survive against blockade of the Hsp system, we treated two human NSCLC cell lines (H1299 and A549) with the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) and Hsp90 inhibitor-resistant NSCLC cell subpopulations. Here, HSP90B2P is linked to non-small cell lung carcinoma.